Efficacy of SLITone in House Dust Mite Allergic Patients

This study has been completed.
Sponsor:
Information provided by:
ALK-Abelló A/S
ClinicalTrials.gov Identifier:
NCT00633919
First received: March 4, 2008
Last updated: June 7, 2011
Last verified: June 2011
  Purpose

This trial has been designed to evaluate the efficacy of specific immunotherapy with SLITone Dermatophagoides mix compared with placebo in subjects with house dust mite allergic asthma, based on asthma medication use during a period of 2 months with a high environmental exposure to mites (autumn 2008).


Condition Intervention Phase
Allergy
Biological: SLITone(TM) Dermatophagoides mix
Biological: Placebo
Drug: Salbutamol inhaler
Drug: Budesonide/formoterol inhaler
Drug: Prednisone tablet
Drug: Desloratadine tablet
Drug: Budesonide nasal spray
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled Trial Assessing the Efficacy of SLITone in House Dust Mite Allergic Patients

Resource links provided by NLM:


Further study details as provided by ALK-Abelló A/S:

Primary Outcome Measures:
  • Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2008 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

    Scoring per inhalation/tablet: 1-2 inhalations twice daily of salbutamol (200 ug per inhalation), 2 scores; 1-2 inhalation twice daily of budesonide/formoterol 80 (4.5 ug per inhalation), 4 scores; 1 inhalation twice daily of budesonide/formoterol 160 (4.5 ug per inhalation), 8 scores; up to 10 tablets once daily of prednisone (5 mg), 1.6 scores. The total maximum daily scores were 40.

    The daily score for each medication step was calculated by multiplying the score per inhalation/tablet with the number of inhalations/tablets used (entered as units in the daily diary by the subject).



Secondary Outcome Measures:
  • Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2007 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

    Scoring per inhalation/tablet: 1-2 inhalations twice daily of salbutamol (200 ug per inhalation), 2 scores; 1-2 inhalation twice daily of budesonide/formoterol 80 (4.5 ug per inhalation), 4 scores; 1 inhalation twice daily of budesonide/formoterol 160 (4.5 ug per inhalation), 8 scores; up to 10 tablets once daily of prednisone (5 mg), 1.6 scores. The total maximum daily scores were 40.

    The daily score for each medication step was calculated by multiplying the score per inhalation/tablet with the number of inhalations/tablets used (entered as units in the daily diary by the subject).


  • Global Evaluation of Efficacy by Subject at the End of The Evaluation Period in 2008 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

    The treatment efficacy was rated by subjects at the end of the evaluation period in autumn 2008. Subjects rated their asthma symptoms in comparison to previous autumn using the categories: "much worse", "worse", "the same", "better", or "much better".

    The categories "much better" or "better" were grouped as "improved". The categories "the same", "worse" or "much worse" were grouped as "not improved".


  • Global Evaluation of Efficacy by Investigator at the End of the Evaluation Period in Autumn 2008 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

    The treatment efficacy was rated by investigators at the end of the evaluation period in autumn 2008. Investigators rated the asthma symptoms in comparison to when subjects entered the trial, using the categories: "much worse", "worse", "the same", "better", or "much better".

    The categories "much better" or "better" were grouped as "improved". The categories "the same", "worse" or "much worse" were grouped as "not improved".


  • Global Evaluation of Efficacy by Subject and Investigator at the End of the Evaluation Period in Autumn 2007 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

    The treatment efficacy was rated by both subject and investigator at the end of the evaluation period in autumn 2007. Subjects rated their asthma symptoms in comparison to previous autumns and investigators rated the asthma symptoms in comparison to when subjects entered the trial, using the categories: "much worse", "worse", "the same", "better", or "much better".

    The categories "much better" or "better" were grouped as "improved". The categories "the same", "worse" or "much worse" were grouped as "not improved".



Enrollment: 124
Study Start Date: July 2006
Study Completion Date: February 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Active
SLITone Dermatophagoides Mix
Biological: SLITone(TM) Dermatophagoides mix
Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
Drug: Salbutamol inhaler
200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
Other Name: Ventilastin
Drug: Budesonide/formoterol inhaler
80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
Other Name: Symbicort
Drug: Prednisone tablet
5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
Drug: Desloratadine tablet
5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
Other Name: Aerus
Drug: Budesonide nasal spray
64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
Placebo Comparator: Placebo
SLITone Placebo
Biological: Placebo
Sublingual immunotherapy once daily for 2 years
Drug: Salbutamol inhaler
200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
Other Name: Ventilastin
Drug: Budesonide/formoterol inhaler
80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
Other Name: Symbicort
Drug: Prednisone tablet
5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
Drug: Desloratadine tablet
5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
Other Name: Aerus
Drug: Budesonide nasal spray
64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A clinical history of house dust mite induced persistent mild to moderate. asthma, with or without concurrent rhinoconjunctivitis, of at least 1 year of evolution.
  • Demonstration of a positive specific serum IgE test to Dermatophagoides during the year prior to the screening visit (CAP Class 2 or higher or equivalent).
  • Positive Skin Prick Test response (wheal diameter ≥ 3 mm) to Dermatophagoides mix.
  • If pre-menopausal female of childbearing potential, the subject must test negative on standard urine pregnancy test.
  • Willingness to comply with this protocol.

Exclusion Criteria:

  • FEV1 < 70% of predicted value with appropriate medication.
  • Asthma controlled at randomization without need of inhaled corticosteroids or with a dose higher than 1000 µg/day of beclometasone or equivalent.
  • A clinical history of symptomatic perennial allergic asthma caused by allergens to which the subjects is regularly exposed (Alternaria, cat), other than house dust mites.
  • Chronic sinusitis.
  • Aspirin or sulfite intolerance.
  • Chronic obstructive pulmonary disease.
  • Current severe atopic dermatitis.
  • Severe asthma.
  • Use of an investigational drug within 30 days prior to screening.
  • Previous immunotherapy with house dust mite allergens for at least 2 years within the previous 10 years.
  • At randomisation, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infectious process (se-rous otitis media is not an exclusion criterion).
  • Physical examination with clinically relevant findings.
  • Any of the following underlying conditions known or suspected to be present: Cystic fibrosis, malignancy, insulin-dependent diabetes, malabsorption or malnutrition, renal or hepatic insufficiency, chronic infection, drug dependency or alco-holism, ischaemic heart disease or angina requiring current daily medication or with any evidence of disease making implementation of the protocol or interpretation of the protocol results difficult or jeopardising the safety of the subject (e.g. clinically significant cardiovascular, serious immunopathologic, immunodeficiency whether acquired or not, hepatic, neurologic, psychiatric, endocrine, or other ma-jor systemic disease).
  • Immunosuppressive treatment.
  • A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the trial, and/or evidence of an uncooperative attitude.
  • Unlikely to be able to complete the trial.
  • Unwillingness to comply with trial protocol regimen for asthma and/or rhinoconjunctivitis medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00633919

Locations
Spain
Fernando Rodríguez
Santander, Cantabria, Spain
Sponsors and Collaborators
ALK-Abelló A/S
Investigators
Study Chair: Santiago Martín, PhD Clinical Research Director, ALK-Abelló, S.A.
  More Information

No publications provided

Responsible Party: Santiago Martín -Trial Manager; ALK-Abelló S.A., ALK-Abelló S.A.
ClinicalTrials.gov Identifier: NCT00633919     History of Changes
Other Study ID Numbers: E02/04/SLIT1-M, EudraCT - 2005-004731-21
Study First Received: March 4, 2008
Results First Received: November 11, 2010
Last Updated: June 7, 2011
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by ALK-Abelló A/S:
House dust mites
Sublingual immunotherapy
Allergy
Allergic asthma

Additional relevant MeSH terms:
Hypersensitivity
Immune System Diseases
Albuterol
Budesonide
Formoterol
Symbicort
Desloratadine
Prednisone
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 01, 2014